These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6783575)

  • 21. Effect of disulfiram on the platelet function and fibrinolysis in healthy volunteers.
    Gleerup G; Boström S; Hansson G; Teger-Nilsson AC; Sjöquist PO; Winther K
    Haemostasis; 1990; 20(4):215-8. PubMed ID: 1700758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of the animal and clinical pharmacology of diflunisal.
    Davies RO
    Pharmacotherapy; 1983; 3(2 Pt 2):9S-22S. PubMed ID: 6344042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease.
    Welles EG; Boudreaux MK; Crager CS; Tyler JW
    Am J Vet Res; 1994 May; 55(5):619-27. PubMed ID: 8067608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired fibrinolytic activity induced by ingestion of butter: effect of increased plasma lipids on the fibrinolytic activity.
    Kozima Y; Urano T; Serizawa K; Takada Y; Takada A
    Thromb Res; 1993 Apr; 70(2):191-202. PubMed ID: 8322287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between structure and activity of aspirin-related compounds on the inhibition of in vitro platelet aggregation.
    Dupin JP; Gravier D; Casadebaig F; Boisseau MR; Bernard H
    Farmaco Sci; 1986 Mar; 41(3):205-14. PubMed ID: 3086120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
    Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
    Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attempts to standardize platelet aggregation measurements: simplified screening tests.
    Kirchhof B; Kirchhof U; Etscheid G
    Haemostasis; 1990; 20(3):169-80. PubMed ID: 2387555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between diflunisal and warfarin.
    Serlin MJ; Mossman S; Sibeon RG; Tempero KF; Breckenridge AM
    Clin Pharmacol Ther; 1980 Oct; 28(4):493-8. PubMed ID: 7408409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis.
    Brogden RN; Heel RC; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Feb; 19(2):84-106. PubMed ID: 6988202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of diflunisal on the pharmacokinetics of oxazepam.
    van Hecken AM; Tjandramaga TB; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1985 Sep; 20(3):225-34. PubMed ID: 4041343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gallopamil and changes of adenosine diphosphate- and collagen-induced thrombocyte aggregation].
    Költringer P; Langsteger W; Lind P; Pierer G; Reisecker F; Eber O
    Arzneimittelforschung; 1991 Aug; 41(8):786-8. PubMed ID: 1781797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat.
    Oyekan AO; Botting JH
    Arch Int Pharmacodyn Ther; 1991; 313():176-92. PubMed ID: 1816761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human platelet aggregation tests in vitro. Effects of dilazep.
    Ponari O; Manotti C
    Arzneimittelforschung; 1981; 31(1):97-101. PubMed ID: 7194099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting effect of feprazone on "in vitro" human platelet aggregation.
    Montanari C; Sala P; Bonardi G; Prandoni E
    Pharmacol Res Commun; 1976 Oct; 8(5):503-9. PubMed ID: 1026972
    [No Abstract]   [Full Text] [Related]  

  • 35. Increase in endogenous fibrinolysis and platelet activity during exercise in young volunteers.
    Beisiegel B; Treese N; Hafner G; Meyer J; Darius H
    Agents Actions Suppl; 1992; 37():183-9. PubMed ID: 1378684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet aggregation in neonates with hyperbilirubinaemia.
    Hiçsönmez G; Prozorova-Zamani V
    Scand J Haematol; 1980 Jan; 24(1):67-70. PubMed ID: 7367834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery.
    Bach J; Kammerer I; Isgro F; Haubelt H; Vogt A; Saggau W; Hellstern P
    Platelets; 2009 May; 20(3):150-7. PubMed ID: 19437331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of Complamin on fibrinolysis and platelet aggregation in the aged].
    Matijević N; Sisić I; Korolija P; Pendić B
    Bilt Hematol Transfuz; 1980; 8(1):37-43. PubMed ID: 7337681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryptolepine inhibits platelet aggregation in vitro and in vivo and stimulates fibrinolysis ex vivo.
    Oyekan AO; Botting JH; Noamesi BK
    Gen Pharmacol; 1988; 19(2):233-7. PubMed ID: 2895035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.